Clinical trials: Rectal Cancer, Radiotherapy
Locally Advanced Rectal Cancer (LARC), 5-12cm to Anal Verge
Iparomlimab and Tuvonralimab Combined With Chemotherapy and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
This study aims to observe and evaluate the efficacy and safety of Iparomlimab and Tuvonralimab（QL-1706） combined with chemotherapy and bevacizumab ± radiotherapy as neoadjuvant therapy in patients with locally advanced rectal…
- Trial name
- IT-CABLE (NCT07769853)
- Testing
- Iparomlimab and Tuvonralimab（QL-1706）combined with Chemotherapy and Bevacizumab
- Volunteers
- 56 people
- Sponsor
- Zhejiang University
Rectal Cancer, Pathological Complete Response
Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial
The purpose of this study was to evaluate the effect of concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX pre- a delayed TME compared with 6 cycles XELOX post- a Regular Timing TME in patients with…
- Conditions
- Rectal Cancer, Pathological Complete Response, Disease Free Survival
- Trial name
- EXPLORE (NCT03038256)
- Testing
- concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME, concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX
- Where
- 2 sites in China
- Volunteers
- 244 people
- Sponsor
- Peking University People's Hospital
Rectal Cancer
Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
The goal of this Phase 2 trial is to evaluate a neoadjuvant treatment mode for locally advanced rectal cancer (LARC), consisting of radiotherapy and concurrent Trifluridine/Tipiracil (TAS-102).
- Trial name
- TASLARC (NCT05965531)
- Testing
- Trifluridine/Tipiracil, intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasms
SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer
This phase II trial studies how well stereotactic body radiotherapy (SBRT) followed by a combination of an immune checkpoint inhibitor (sintilimab), bevacizumab, and trifluridine/tipiracil (TAS-102) works as third-line treatment…
- Trial name
- BEST (NCT07535632)
- Testing
- SBRT, Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai Zhongshan Hospital
Cervical Cancer, Endometrial Cancer
Study of Vaginal Dilator Use After Pelvic Radiotherapy
Patient will have radiation to treat the cancer. This treatment can make the vagina both narrower and shorter. That can cause two problems. It can make it harder for the doctor to do a pelvic exam during a follow-up visits.
- Conditions
- Cervical Cancer, Endometrial Cancer, Rectal Cancer, Anal Cancer
- Trial name
- NCT00789893
- Testing
- Vaginal Dilator
- Where
- 5 sites in United States
- Volunteers
- 115 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Recurrent Rectal Cancer
Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)
This is an open-label, single arm, phase 2 study. The study is to evaluate the activity of combination therapy of hypofractionated radiotherapy, Irinotecan Hydrochloride Liposome plus 5-FU and leucovorin (NALIRIF), Anti-PD1 and…
- Trial name
- NCT07183865
- Testing
- radiotherapy, Irinotecan Hydrochloride Liposome, 5-FU
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fudan University
Rectal Cancer
Intersphincteric Resection With or Without Intraoperative Radiation in Rectal Cancer
The purpose of this study was to research on the safety and feasibility of ISR combined with low energy X ray intra-operative radiotherapy for the patients with local advanced rectal cancer.
- Trial name
- IDAVON (NCT03393234)
- Testing
- Interoperative radiation by INTRABEAM using low energy X-ray
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Hospital of Jilin University
Colorectal Cancer
A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.
This open-label study will assess the efficacy and safety of Avastin (bevacizumab) plus Xeloda (capecitabine) in combination with standard technique radiotherapy of the pelvic region in the neo-adjuvant setting in patients with…
- Trial name
- NCT01227707
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], Radiation therapy
- Where
- 9 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Rectal Adenocarcinoma
Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer
A Prospective Single-Arm Study of Short-Course Radiotherapy Followed by PD-1 Monoclonal Antibody, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil for Total Neoadjuvant Therapy in MSS Locally Advanced Low Rectal Cancer.
- Trial name
- SCRIPBOT (NCT06872606)
- Testing
- Pucotenlimab, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sir Run Run Shaw Hospital
Rectal Cancer, Neoadjuvant Therapies
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
Most rectal cancers are microsatellite stable (MSS) or mismatch repair-proficient (pMMR) and respond poorly to PD-1 inhibitors. Radiotherapy can enhance tumor antigen release and improve responsiveness to PD-1 blockade in…
- Conditions
- Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy
- Trial name
- NCT06958432
- Testing
- Node-Sparing Radiotherapy plus Chemotherapy and PD-1 inhibitor, Conventional Radiotherapy plus Chemotherapy
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Radiation-induced Injuries in Patients With Rectal Cancer
Effectiveness of Vitamin E and Hydrogen-Rich Water on Radiation Therapy-Induced Adverse In Patients With Rectal Cancer
Controlled studies investigating the effects of vitamin E or H2 water or comparing their effectiveness on radiation therapy-induced injuries in RC patients are generally lacking.
- Trial name
- NCT04713332
- Testing
- Vitamin E, Hydrogen rich water
- Where
- Palestinian Territories
- Volunteers
- 60 people
- Sponsor
- University of Jordan
Rectal Cancer
Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
The goal of this clinical trial is to evaluating the efficacy and safety of radiotherapy combined with Tislelizumab, Liposomal Irinotecan, and Capecitabine in patients with locally advanced mid-lower rectal cancer with pMMR..
- Trial name
- NCT07104604
- Testing
- Liposomal Irinotecan+Tislelizumab+Capecitabine+Rradiotherapy
- Where
- 2 sites in China
- Volunteers
- 51 people
- Sponsor
- Affiliated Cancer Hospital of Shantou University Medical College
Locally Advanced Rectal Cancer
Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer
The study evaluates the addition of Amifostine to capecitabine and irinotecan in neoadjuvant chemoradiation(CRT) in locally advanced rectal cancer.
- Trial name
- NCT03702985
- Testing
- Radiation, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Anal Squamous Cell Carcinoma, Limited-stage
Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma
This is a prospective, multicenter, open-label, phase III randomized controlled clinical trial designed to evaluate the efficacy and safety of replacing the traditional chemotherapeutic drug mitomycin with the PD-1 inhibitor…
- Trial name
- NCT07692152
- Testing
- Intensity-Modulated Radiotherapy (IMRT), Capecitabine, Sintilimab
- Where
- 2 sites in China
- Volunteers
- 350 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rectal Cancer
Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer
This study is being done to look at the safety and response to the investigational drug durvalumab (MEDI4736) following chemo-radiation therapy for patients with MSS stage II to IV rectal cancer.
- Trial name
- NCT03102047
- Testing
- durvalumab
- Where
- 43 sites in United States
- Volunteers
- 45 people
- Sponsor
- NSABP Foundation Inc
Anal Cancer, Radiotherapy Side Effect
Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II
This study proposal includes a prospective clinical trial of bone sparing treatment planning in anal cancer patients. the trial aim to lower the risk of bone damage, while adhering with the constrains to the bowel, bladder and…
- Trial name
- DACG-II (NCT05385250)
- Testing
- Bone sparring radiotherapy
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Karen-Lise Garm Spindler
Local Advanced Rectal Cancer, Radiotherapy
Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer
This multicenter, randomized, controlled, phase III trial evaluates whether adding iparomlimab and tuvonralimab injection to CAPOX consolidation chemotherapy after short-course radiotherapy improves tumor response in patients…
- Conditions
- Local Advanced Rectal Cancer, Radiotherapy, Immunotherapy
- Trial name
- SCRIT (NCT07686640)
- Testing
- Short-Course Radiotherapy, Consolidation treatment (With ICIs), Consolidation treatment (Without ICIs)
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shandong Cancer Hospital and Institute
Localized Anal Carcinoma, Localized Anal Margin Carcinoma
Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment
This clinical trial studies how well ganglion impar neurolysis works to improve radiation-induced pain during the treatment of anal or perianal skin cancer that has not spread to other parts of the body (localized).
- Conditions
- Localized Anal Carcinoma, Localized Anal Margin Carcinoma, Stage 0 Anal Cancer AJCC v8, Stage I Anal Cancer AJCC v8
- Trial name
- NCT07112690
- Testing
- Electronic Health Record Review, Fluoroscopy, Ganglion Impar Neurolysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Locally Advanced Rectal Cancer
Observational Study on Rectal Cancer to Verify if Response After Chemo-radiotherapy Can be Predicted With a Particular Blood Test.
Research project for patients with locally advanced rectal cancer in which biological material and health-related personal data are collected.
- Trial name
- LiBReCa (NCT03699410)
- Testing
- Neoadjuvant radiotherapy, Neoadjuvant chemotherapy, Radical surgery
- Where
- 2 sites in Switzerland
- Volunteers
- 25 people
- Sponsor
- Dimitri Christoforidis
Colon Cancer, Rectal Cancer
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
The purpose of this study is to find out how well patients with cancer of the rectum do if they get all of their other treatment - chemotherapy by itself followed by chemotherapy and radiation together - before surgery.
- Trial name
- NCT01363843
- Testing
- FOLFOX6, RT with concurrent chemotherapy, Surgery
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- William Sikov MD